Ingrezza Improved Quality of Life and Daily Function in People with Tardive Dyskinesia
KEY TAKEAWAYS
- Patient-reported tardive dyskinesia impact improved by 8.0 points at week 24, exceeding the established threshold for clinically meaningful change.
- Clinician-rated movement severity improved beyond the threshold for clinically meaningful change, including among participants with mild tardive dyskinesia at baseline.
- Approximately 58% of evaluable participants met the study definition of symptomatic remission at week 24.
Once-daily Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) was associated with improvements in patient-reported quality of life and daily functioning, along with reduced movement severity, in adults with tardive dyskinesia (TD) in the phase 4 KINECT-PRO study. Improvements were observed across baseline movement severity, including among participants with clinician-rated mild TD.
KINECT-PRO enrolled 59 adults with at least mild TD and schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder. Participants received Ingrezza 40 mg once daily for 4 weeks, followed by flexible dosing of 40, 60, or 80 mg through week 24. Fifty-two participants completed the study, and 45 were included in efficacy analyses. Primary outcomes assessed patient-reported TD impact, daily functioning, and overall health using the Tardive Dyskinesia Impact Scale (TDIS), Sheehan Disability Scale (SDS), and EuroQoL Visual Analogue Scale (EQ-VAS).
What the KINECT-PRO Data Showed
- TDIS scores improved by a mean 8.0 points at week 24, exceeding the 4-point threshold for clinically meaningful change.
- Abnormal Involuntary Movement Scale (AIMS) scores improved by a mean 6.8 points, exceeding the 2-point clinically meaningful change threshold.
- Self-rated overall health on the EQ-VAS improved by a mean 13.1 points.
- Among participants with mild TD at baseline, TDIS and AIMS scores improved by 6.8 and 5.6 points, respectively.
- 26 of 45 participants (58%) met the study definition of symptomatic remission at week 24, defined as no more than minimal movement severity across the 7 AIMS body regions.
Safety and tolerability were consistent with the established profile of Ingrezza, with no new safety concerns reported. KINECT-PRO was a small, open-label study without a placebo or active comparator, limiting conclusions about the magnitude of treatment-related effects.
Source:
Correll CU, Perez-Rodriguez MM, McEvoy JP, et al. Valbenazine improves quality of life, functionality, and movement severity in patients with tardive dyskinesia: findings from the KINECT-PRO study. CNS Spectr. Published online 2026. doi:10.1017/S1092852926101138